Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids
View Patent ↗A composition, useful in the prevention of osteoporosis, wherein said composition comprises (a) least one isoflavone and/or isoflavone glycoside, preferably genistein and/or genistin; (b) at least one polyunsaturated fatty acid; (c) optionally vitamin D, and /or one or more derivatives thereof and/or vitamin K and/or one or more derivatives thereof; and (d) optionally adjuvants and excipients in quantities as required, preferably within the range of 0.1 to 20% by weight, based on the total weight of the composition. Dietary compositions and galenical forms made therefrom and the use of said compositions for preventing osteoporosis and stimulating osteogenesis in mammals.
1. A composition useful for the treatment of osteoporosis consisting of a mixture of the following components:
(a) genistein, genistin, or a mixture thereof;
(b) a docosahexaenoic acid (DHA); and
(c) optionally a vitamin which is selected from the group consisting of vitamin D, vitamin D 3 , vitamin K, vitamin K 1 , and mixtures thereof.
2. The composition according to claim 1 , wherein the DHA is (cis-)4,7,1 0,13,16,19-docosahexaenic acid.
3. The composition according to claim 2 , wherein said composition is provided in a form selected from the group consisting of concentrates, granules, tablets, pastes filled into hard or soft gelatine capsules, and effervescent formulations.
4. A dietary composition in the form of a fortified feed or a beverage, comprising a composition according to claim 2 .
5. A galenical formulation in the form of tablets, granules, pastes filled into hard or soft gelatine capsules, or effervescent formulations, comprising a composition according to claim 2 .
6. The composition according to claim 1 , wherein the DHA is in an amount of from 50 mg to 8000 mg.
7. The composition according to claim 6 , wherein the DHA is in an amount in the range of from 500 mg to 2000 mg.
8. The composition according to claim 1 , wherein about 5 to 200 mg of DHA is present per mg of component (a).
9. The composition according to claim 1 , wherein the amount of each of vitamin D and vitamin D 3 is in the range of from 5 μg to 50 μg, and the amount of each of vitamin K and vitamin K 1 is in the range of from 0.050 mg to 10 mg.
10. The composition according to claim 1 wherein, said composition is provided in a form selected from the group consisting of concentrates, granules, tablets, pastes filled into hard or soft gelatine capsules, and effervescent formulations.
11. The composition of claim 10 in the form of a concentrate which is a simple powdery mixture of its components.
12. The composition in the form of granules according to claim 10 obtainable by fluidized-bed granulation, high-shear granulation, extrusion, spray-drying or wet granulation.
13. A dietary composition in the form of a fortified feed or a beverage, comprising a composition according to claim 1 .
14. A galenical formulation in the form of tablets, granules, pastes filled into hard or soft gelatine capsules, or effervescent formulations, comprising a composition according to claim 1 .
15. A composition for use in the treatment of osteoporosis and for osteogenesis in mammals, said composition comprising the following components:
(a) genistein in the range of from 5 to 100 mg;
(b) a docosahexaenoic acid (DHA);
(c) a vitamin which is selected from the group consisting of vitamin D, vitamin D 3 , and mixtures thereof in the range of from 5 μg to 50 μg;
(d) a vitamin which is selected from the group consisting of vitamin K, vitamin K 1 , and mixtures thereof in the range of from 0.050 mg to 10 mg; and
(e) optionally adjuvants and or excipients.
16. The composition according to claim 15 wherein about 5 to 200 mg of DHA is present per mg of genistein.
17. The composition according to claim 15 wherein adjuvants and or excipients are present from 0.1 to 20% by weight, based on the total weight of the composition.